Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/4/2019
SIETES contiene 92718 citas

 
 
 1 a 20 de 114 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]
2. Cita con resumen
Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med 2016;44:1842-50. [Ref.ID 100852]
3. Cita con resumen
Anónimo. Comparative effectiveness of proton pump inhibitors. Therapeutics Initiative Evidence Based Drug Therapy 2016;99:1-2. [Ref.ID 100573]
4. Cita con resumen
Dyer O. Physician whistleblower is awarded $59m in Pfizer settlement. BMJ 2016;352:i1195. [Ref.ID 100326]
5.Enlace a cita original Cita con resumen
Begley J, Smith T, Burnett K, Strike P, Azim A, Spake C, Richardson T. Proton pump inhibitor hypomagnasemia - a cause for concern?. Br J Clin Pharmacol 2016;81:753-8. [Ref.ID 100179]
6. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016:14 de abril. [Ref.ID 100161]
7. Cita con resumen
Anónimo. Pfizer settles Medicaid claims for $785 million. DIA Daily 2016:1. [Ref.ID 100000]
8. Cita con resumen
Olsen A-MS, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbøl E, Køber L, Torp-Pedersen C, Lamberts M. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ 2015;351:h5096. [Ref.ID 99631]
9. Cita con resumen
Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]
10. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
11. Cita con resumen
Anónimo. Which PPI?. Med Lett Drugs Ther 2015;57:8-9. [Ref.ID 99216]
12. Cita con resumen
Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, Nead KT, Cooke JP, Leeper NJ. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015:10 de junio. [Ref.ID 99197]
13.Tiene citas relacionadas Cita con resumen
Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Buttò V, Ferrucci L, Bandinelli S, Abbatecola AM, Spazzafumo L, Lattanzio F. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013;173:518-23. [Ref.ID 95257]
14.Enlace a cita original Cita con resumen
Madrilejos R. Inhibidors de la bomba de protons i el balanç risc/benefici. Butlletí d'Informació Terapèutica 2013;24:7-11. [Ref.ID 94629]
15.Enlace a cita original
Dworzynski K, Pollit V, Kelsey A, Higgins B, Palmer K, on behalf of the Guideline Development Group. Management of acute upper gastrointestinal bleeding: summary of NICE guidance. BMJ 2012;344:45-7. [Ref.ID 93219]
16.Enlace a cita original Cita con resumen
Anónimo. Riesgo de hipomagnesemia asociado a los medicamentos inhibidores de la bomba de protones (IBP). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2011:1-3. [Ref.ID 91777]
17. Cita con resumen
Furlanetto TW, Faulhaber GAM. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011;171:1391-2. [Ref.ID 91365]
18. Cita con resumen
Anónimo. PPIs: too much of a good thing?. Drug Ther Bull 2011;49:49. [Ref.ID 91280]
Seleccionar todas
 
 1 a 20 de 114 siguiente >>